Recent studies and anecdotal reports suggest that psychedelics can improve mood states, even at low doses. However, few placebo-controlled studies have examined the acute effects of low doses of LSD in individuals with psychiatric symptoms. In the current study, we examined the acute and sub-acute effect of a low dose of LSD (26 µg) on subjective effects and mood in volunteers with mild depressed mood. The study used a randomized, double-blind, crossover design to compare the effects of LSD in two groups of adults: participants who scored high (≥17; n = 20) or low (<17; n = 19) on the Beck Depression-II inventory (BDI) at screening. Participants received a single low dose of LSD (26 µg) and placebo during two 5-h laboratory sessions, separated by at least one week. Subjective, physiological, and mood measures were assessed at regular intervals throughout the sessions, and behavioral measures of creativity and emotion recognition were obtained at expected peak effect. BDI depression scores and mood ratings were assessed 48-h after each session. Relative to placebo, LSD (26 µg) produced expected, mild physiological and subjective effects on several measures in both groups. However, the high BDI group reported significantly greater drug effects on several indices of acute effects, including ratings of vigor, elation, and affectively positive scales of a measure of psychedelic effects (5D-ASC). The high BDI group also reported a greater decline in BDI depression scores 48-h after LSD, compared to placebo. These findings suggest that an acute low dose of LSD (26 µg) elicits more pronounced positive mood and stimulant-like effects, as well as stronger altered states of consciousness in individuals with depressive symptoms, compared to non-depressed individuals.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10948752 | PMC |
http://dx.doi.org/10.1038/s41386-023-01772-4 | DOI Listing |
Alzheimers Dement
December 2024
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: The ability to monitor cognitive trajectories over the course of trials can provide valuable insights into treatment efficacy. However, existing trial methods are limited in monitoring cognition in real-time and at high frequencies. Gameplay-based assessments hold promise as complementary cognitive tools.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Background: To support informal caregivers of persons with dementia (PwD), it is fundamental to understand how objective and subjective indicators of care burden are interrelated. This study used psychometric network analyses to explore care burden indicators and extend current models of care in informal caregivers of PwDs.
Methods: Baseline data from an intervention study of 170 informal caregivers of community-dwelling PwDs was used.
Alzheimers Dement
December 2024
Arizona State University, Phoenix, AZ, USA.
Background: Subjective cognitive decline (SCD) represents an important therapeutic target to prevent future cognitive decline associated with aging as well as neurodegenerative diseases such as Alzheimer's disease. One such therapy is the "dual-task" exergaming with concurrent aerobic exercise (AEx) and cognitive training. The primary aim of this Stage IB randomized controlled trial (RCT) was to test the preliminary effects of a dual-task exergaming telerehabilitation intervention on cognition and aerobic fitness, in comparison to AEx only and attention control (stretching) in older adults with SCD METHOD: This RCT randomized 39 participants on a 2:1:1 allocation ratio to supervised exergame (Figure 1) (n = 20), AEx (n = 11), and stretching (n = 8), 3 times a week for 12 weeks.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Background: Context-specific measures with high content validity are needed to adequately determine psychosocial effects related to screening for cognitive impairment. The objective of this investigation was to examine psychometric properties of the Psychological Consequences of Screening Questionnaire (PCQ), a measure of psychological impact of medical screening, adapted for cognitive screening in primary care.
Methods: Two-hundred adults aged ≥65 recently completing routine, standardized cognitive screening as part of their Medicare Annual Wellness Visit were administered the adapted PCQ measure, comprised of negative (PCQ-Neg) and positive (PCQ-Pos) scales.
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany.
Background: Environmental factors account for a considerable percentage of dementia cases. Studies in animal models have shown that environmental enrichment (EE; i.e.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!